Exploring the effects of a diabetes medication on metabolic health in patients receiving teplizumab.
Official title: Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab
Funded at Vanderbilt University Medical Center · NIH-11056791 · Data updated 2026-11-12
This study is looking at how a medication called GLP-1Ra can help people with stage 2 type 1 diabetes who are also taking teplizumab, to see if it can protect their insulin-producing cells and possibly delay the need for insulin therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $285,975 |
| NIH project number | 5R01DK139322-02 |
| Project ID | NIH-11056791 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with stage 2 type 1 diabetes who are currently receiving teplizumab treatment.
✕Less likely to help
Patients with advanced type 1 diabetes or those not receiving teplizumab may not benefit from this research.
What this research studies
This research investigates how glucagon-like peptide-1 receptor agonists (GLP-1Ra) can improve metabolic outcomes in individuals with stage 2 type 1 diabetes who are also receiving teplizumab, an immunomodulatory treatment. The study aims to understand the potential of GLP-1Ra to slow down the decline of insulin-producing beta cells and delay the need for insulin therapy. By examining the combined effects of these treatments, the research seeks to fill existing knowledge gaps and propose new, personalized treatment strategies for managing early-stage type 1 diabetes.
Why it matters
Potential benefit: If successful, this research could lead to improved management of type 1 diabetes, potentially delaying the need for insulin therapy and enhancing long-term metabolic health.
How similar studies have gone: While the combination of GLP-1Ra and teplizumab is a novel approach, previous studies have shown promise in using GLP-1Ra for metabolic improvements in diabetes management.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Gregory, Justin — Vanderbilt University Medical Center
- Study coordinator: Gregory, Justin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.